Aurobindo Pharma has issued a clarification regarding significant volume movement in the company’s shares. The company states that it is compliant with disclosure obligations. A recent government notification regarding Minimum Import Price (MIP) on certain products has led to media coverage. The company asserts that all relevant information is already public and that the recent trading volume appears market-driven.
Response to Volume Increase
Aurobindo Pharma has addressed queries regarding recent significant volume movements in its securities, stating that the company has been making timely and adequate disclosures to the exchanges.
MIP Impact and Public Disclosure
The company acknowledges media coverage regarding the potential impact of the Government of India’s notification imposing a Minimum Import Price (MIP) on Penicillin-G, 6-Aminopenicillanic Acid (6-APA), and Amoxicillin Trihydrate. It emphasizes that details of this notification are already publicly available on the Government’s DGFT website. This information is in the public domain, and the company believes there is no further specific information requiring additional disclosure.
Market-Driven Securities Trading
Aurobindo Pharma believes the recent increase in the trading volume of its securities appears to be driven purely by market forces. The company affirms that, as of January 30, 2026, there is no other undisclosed information or announcement that could affect the price or volume movement of its securities.
Source: BSE
